Tezepelumab is an anti-TSLP human monoclonal antibody that normalizes type 2 cytokine levels (9) and in clinical studies significantly reduced exacerbation rates vs placebo in patients with severe, uncontrolled asthma (10). Here, TSLP is linked to asthma.